CB 1 receptor signalling is canonically mediated through inhibitory Gα i proteins, but occurs through other G proteins under some circumstances, Gα s being the most characterized secondary pathway. Determinants of this signalling switch identified to date include Gα i blockade, CB 1 /D 2 receptor co-stimulation, CB 1 agonist class and cell background. Hence, we examined the effects of receptor number and different ligands on CB 1 receptor signalling.
Introduction
Despite longstanding consensus as to its canonical Gα imediated signalling pathway, the type one cannabinoid receptor (CB 1 ) is among several GPCRs now understood to transduce signals through more than one G protein effector -a capacity sometimes referred to as 'promiscuous G protein coupling' (reviewed in Maudsley et al., 2005) . Environmental and pharmacological conditions that have been found to affect CB 1 receptor signalling in this way include blockade of the canonical Gα i pathway with pertussis toxin (PTX) (Glass and Felder, 1997; Bonhaus et al., 1998; Scotter et al., 2010) , the class of CB 1 agonist (Bonhaus et al., 1998; Lauckner et al., 2005) , receptor oligomers (Kearn et al., 2005; Bagher et al., 2016) and cell background (McIntosh et al., 2007) .
The CB 1 receptor was first seen to demonstrate Gα s -like signalling behaviour under conditions of co-stimulation with the type two dopamine receptor (D 2 ) in primary rat striatal neurons: on stimulation with quinpirole (a specific D 2 receptor agonist) or HU210 (a CB 1 receptor agonist) alone, these neurons demonstrated the expected inhibition of forskolin-induced cAMP, but when HU210 was applied in addition to quinpirole, this inhibitory signal was reversed in a concentration-dependent manner (Glass and Felder, 1997) . In both primary cells and transfected cell lines stably expressing CB 1 receptors, PTX pretreatment has also been found to unmask this Gα s -like signalling phenotype, in the absence of D 2 receptor co-expression/co-stimulation (Glass and Felder, 1997; Bonhaus et al., 1998; Scotter et al., 2010) . These observations gave rise to the hypothesis that Gα s -like CB 1 receptor signalling arose in circumstances when the availability of Gα i was limited ('Gα i exhaustion'), either because Gα i was directly inactivated by PTX or because it was sequestered by other Gα i -coupled receptors (of which the D 2 receptor is an example). However, Jarrahian et al. (2004) have reported that the mere co-expression of CB 1 and D 2 receptors is sufficient for a CB 1 receptor-mediated Gα s -like cAMP phenotype to be unmasked, a finding which appears to require either G protein pre-coupling (Ferre, 2015) or high levels of D 2 receptor-mediated constitutive signalling for the Gα i exhaustion hypothesis to hold. Subsequently, co-immunoprecipitation data led Kearn et al. (2005) to propose that the CB 1 receptor signalling switch is derived pleiotropically, from altered protein conformations caused by a physical interaction between D 2 and CB 1 receptors -a receptor heterodimer. Characterization of the CB 1 /D 2 receptor heterodimer has continued using other approaches (Marcellino et al., 2008; Przybyla and Watts, 2010; Bagher et al., 2016) . It remains noteworthy that the two hypotheses of the signalling switch mechanism need not be mutually exclusive, and both promiscuous (lowefficacy activation of a non-preferred G protein species due to lack of availability of the preferred species; i.e. Gα i exhaustion) and pleiotropic (stoichiometric/conformational) mechanisms have precedent in the literature (Zhu et al., 1994; Laugwitz et al., 1996; Cordeaux et al., 2000; Jin et al., 2001) .
The exact identity of the G protein subtype that mediates the novel effects was not originally shown directly (Glass and Felder, 1997) , although the stimulatory cAMP effect and absence of PTX sensitivity suggested CB 1 receptor coupling to Gα s . Abadji et al. (1999) demonstrated that the CB 1 receptor contains a conserved two amino acid motif that mediates Gα s coupling of the β-adrenoceptor, but Bash et al. (2003) provided the first direct evidence of some Gα s protein involvement by demonstrating that anti-Gα s antibodies could knock down CB 1 receptor-mediated Ca 2+ flux. Very recently, Eldeeb et al. (2016) showed specific, direct Gα s protein involvement in CB 1 receptor signalling using a scintillation proximity variant of a [ 35 S]-GTPγS assay, in a study that underscores the relevance of the CB 1 receptormediated Gα s signalling pathway by demonstrating its presence under experimental conditions where agonism does not induce a nett stimulatory cAMP signal. Recently, we have observed Gα s -like signalling of CB 1 receptor in assays where the receptor is expressed transiently. This expression method frequently results in very high transgene expression primarily due to cellular uptake of multiple copies of the transfected construct. In stably expressing cell lines, high levels of transgene expression can be produced by molecular engineering of an N-terminal signal sequence tag such as the preprolactin signal sequence (pplss). This is a short (30 amino acid) peptide, which substantially increases the efficiency of nascent protein secretion by acting as a recognition sequence for the signal recognition particle (SRP) (Kurzchalia et al., 1986) , but is cleaved during maturation and therefore does not alter protein function (Belin et al., 1996) . Based on our observations, we hypothesized that CB 1 receptor number is a novel determinant of the Gα i -Gα s signalling switch and have therefore systematically characterized the relationship between receptor expression and CB 1 receptor signalling. A panel of six chemically distinct CB 1 agonists was compiled to allow delineation of ligand-dependence of the two signalling pathways.
Methods

Molecular biology
The pEF4A (Thermo Fisher Scientific, Waltham, MA, USA) plasmid encoding human CB 1 chimerized with three Nterminal haemagglutinin (HA) tags (3HA-hCB 1 ) has been described previously (Cawston et al., 2013) . The coding region for bovine pplss was amplified by PCR from a plasmid kindly gifted by Professor Ken Mackie (Indiana University, Bloomington, IN, USA) with primers designed to incorporate KpnI restriction sites at either end of the amplicon. The pplss sequence was then incorporated into the 3HA-hCB 1 pEF4A plasmid by non-directional KpnI restriction cloning, and sequence verified.
Cell culture and transfection
Cell culture media and reagents were purchased from Thermo Fisher Scientific, and plasticware was purchased from Corning (Corning, NY, USA). HEK293 cell lines were cultured in DMEM supplemented with 10% FBS and an appropriate selection of antibiotics and were cultured in 5% CO 2 , at 37°C in a humidified incubator.
The HEK cell line stably expressing 3HA-hCB 1 receptors has been described previously (Cawston et al., 2013) . This cell BJP D B Finlay et al.
line was used as the background to generate a HEK cell line that co-expresses CB 1 and D 2 receptors, and is first described in Hunter et al. (2016) . The HEK cell line stably expressing the human 3HA-hCB 2 receptor has also been described previously (Grimsey et al., 2011) . The pplss-3HA-hCB 1 pEF4A construct (described above) was linearized and stably transfected into the same wild-type HEK cell background using Lipofectamine 2000. A clonal population of cells expressing receptors at qualitatively high levels was then isolated and propagated for subsequent experiments. Wild-type HEK Flp-In ™ -293 cells (Thermo Fisher Scientific) were also stably transfected with a modified pcDNA3L-His-cAMP sensor Venus-Epac-Rluc8 (V8-CAMYEL) plasmid (Hunter et al., 2017) (as distinct from the original CAMYEL biosensor which was used in assays described below, using the same random incorporation method of stable transfection (i.e. the Flp Recombination Target site (FRT) was left unoccupied). This cell line was used for assays involving transient receptor expression and FACS.
Assays for cAMP where CB 1 receptors were expressed stably Cellular cAMP was measured using a commercially available kinetic BRET assay (CAMYEL), as previously described (Jiang et al., 2007; Cawston et al., 2013) . In brief, sufficient cells were seeded in 10 cm dishes such that they would be approximately 60% confluent the next day. The day after seeding, culture medium was replaced and 5 μg of an expression construct encoding the CAMYEL biosensor (pcDNA3L-His-CAMYEL) was transfected using linear polyethylenimine (PEI, MW Saturation binding assays to characterize AM6544. Saturation binding assays were performed in the Makriyannis laboratory to characterize the novel irreversible antagonist of CB 1 receptors, AM6544 ( Figure 4A ) (Patent US8084451, 2011). Irreversible labelling assays were performed as described previously (Janero et al., 2015; Hua et al., 2016) . HEK293F cell P2 membranes containing the hCB 1 receptor were purified as described previously (Xu et al., 2005) and were resuspended at a concentration of 1 mg·mL À1 in TME buffer (25 mM Tris Base, 5 mM MgCl 2 , 1 mM EDTA, pH 7.45) containing 1 mg·mL À1 w . v -1 BSA and incubated with 10× K i (~100 nM) of AM6544 or SR141716A (or DMSO vehicle) at 30°C for 1 h with gentle agitation. The reaction was terminated by centrifugation at 27 000 × g for 10 min, followed by removal of excess unbound ligand by washing. Pellets were resuspended in TME buffer containing 1 mg·mL À1 BSA and incubated at 30°C for 30 min with gentle agitation. This centrifugation and resuspension was repeated. After a final centrifugation, membrane pellets were resuspended in TME containing 1 mg·mL À1 BSA, and Whole cell binding assays. For whole cell binding assays, pplss-3HA-hCB 1 HEK cells were plated in poly-D-lysine coated 24-well plates and were cultured overnight. The next day, cell confluency was approximately 80%. For live cell assays to determine AM6544 washout ('live cell affinity/irreversibility'), a concentration series of AM6544 was prepared in serum-free medium supplemented with 1 mg·mL À1 BSA and incubated with the cells under conditions described above for the CAMYEL assays (volume adjusted for same well surface area : volume ratio, and 37°C for 1 h). At the end of the AM6544 pretreatment, wells were BJP D B Finlay et al.
washed twice with warm HBSS, and the binding assay was initiated.
[ 3 H]-SR141716A was diluted in serum-free medium supplemented with 1 mg·mL À1 BSA; dilution series of non-tritiated drugs were prepared in this mixture where applicable and dispensed into the 24-well plate. Cells were incubated with radioligand for 1 h at 30°C. At the end of the incubation, the plate was moved to ice, well contents were removed with a vacuum and wells were gently washed twice with ice-cold PBS. Cells were lysed with 250 μL per well 0.1 M NaOH in milliQ water. Lysates (200 μL per well) were moved to 4 mL scintillation tubes and diluted in excess volumes of scintillation fluid. Scintillation was read in the TriLux Counter (as above) following a 6 h delay, to allow time for the aqueous lysate to fully disperse in the scintillation fluid.
Phospho-ERK assays
Characterization of the activation by phosphorylation of ERK (pERK) was performed using the commercially available AlphaScreen SureFire kit (Perkin Elmer). In brief, cells were plated in 96-well culture plates and then after 24 h of culture were serum starved for >16 h (in serum free medium supplemented with 1 mg·mL À1 BSA) prior to stimulation, in the presence or absence of PTX (100 ng·mL À1 ). Drugs were prepared in serum-free medium supplemented with 1-mg·mL À1 BSA, and then pERK time courses were performed with plates resting on a barely submerged stage in a 37°C waterbath. At the conclusion of the time course, plates were placed on ice, well contents were removed by aspiration, and cells were immediately lysed in 30 μL of lysis buffer. Subsequently, AlphaScreen detection was performed according to manufacturer instructions, and plates were read in a CLARIOstar® plate reader (BMG Labtech, Ortenberg, Germany).
Data and statistical analysis
BRET cAMP time course data were analysed using AUC analysis, as described in Finlay et al. (2016) . Data were normalized to basal (0%) and forskolin alone (100%) in order to enable a combination of independent experiments (accounting for small differences in forskolin-induced cAMP levels between replicates). Concentration-response parameters were obtained by fitting three-parameter (Hill coefficient constrained to 1) nonlinear regression curves. Where concentration-response curves could not be fitted, connecting lines were drawn between data points to help visualize trends, including for U-shaped responses. Plots show representative data (mean ± SEM) of technical replicates, unless otherwise specified. All statistical analyses (see below) were performed using data from biological (independent) replicates. Operational analysis for ligand bias (van der Westhuizen et al., 2014) and all plots and curve-fits were obtained using GraphPad Prism v6 (GraphPad Software Inc., La Jolla, CA, USA).
Homologous binding data were modelled utilizing the predefined equations in GraphPad Prism, producing log K ) was then used to convert bound radioligand into mmol radioligand bound, and this was normalized for protein amount.
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Power analysis for cAMP assays was performed using data from pilot experiments, for both EC 50 (minimum effect difference of 0.7 log M) and E MAX (minimum effect difference of 20% of the matched forskolin response). The values for α and power were 0.05 and 0.80 respectively. All final datasets were tested for compliance with parametric test assumptions of normality (Shapiro-Wilk) and equality of variance (Levene Median). If the tested population failed to meet either assumption, data were transformed and re-tested. Where statistical tests were utilized (one-or two-way ANOVA, as appropriate, unless otherwise specified), data were obtained from at least five biological replicates of each experiment. Where statistically significant differences (P < 0.05) were detected across the entire group in the test, the Holm-Šídák post hoc test was used. All statistical analysis was performed using SigmaPlot ™ v12.5 (Systat Software Inc., San Jose, CA, USA). Data presented in figures are either 'representative' (illustrative data from a single experiment, consistent with data from independent replicates) or 'combined' (summary data, where all replicates' results were averaged) of five independent experiments unless otherwise indicated. This approach was necessary in order to preserve the statistical meaningfulness of parameters from concentration-response curves, as explained in detail by Hall and Langmead (2010) .
Drugs
Forskolin, CP55,940, WIN55,212-2 and BAY59-3074 (BAY) were purchased from Tocris Bioscience (Bristol, UK); anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) were purchased from Cayman Chemical Company (Ann Arbour, MI, USA); and (-)-trans-Δ 9 -tetrahydrocannabinol (THC) was purchased from THC Pharm GmbH (Frankfurt, Germany). U0126 was purchased from Cell Signalling Technology (Danvers, MA, USA), and PMA and quinpirole hydrochloride were purchased from Sigma Aldrich (St Louis, MO, USA). SR141716A (rimonabant) was a gift from Roche (Basel, Switzerland). Drug stocks were prepared in absolute ethanol (CP55,940, WIN55,212-2, AEA, 2-AG, THC, BAY) or DMSO (forskolin, AM6544, SR141716A) and were stored in aliquots at À80°C prior to use. Drug aliquots used for experiments involving serial dilutions were always single-use, to minimize assay drift due to solvent evaporation or chemical decay from freeze-thaw cycles. Vehicle controls for serial dilutions were maintained constant within experiments, and cell exposure to solvents was minimized (0.1-0.3%). In order to assuage concerns about endogenous cannabinoids in serum, all drug stimulations were performed in the absence of FBS and following a period of serum starvation.
Results
Gα s -mediated signalling unmasks agonist bias and is specific for CB 1 receptors
Using the CAMYEL assay, cAMP concentration-response curves were obtained for six CB 1 agonists in (not pplsstagged) 3HA-hCB 1 HEK cell line, following pretreatment both in the absence and presence of PTX. These data revealed that all six agonists act with substantial efficacy in the Gα i pathway (Table 1 ; Figure 1A) , with THC and BAY, reported partial agonists (De Vry et al., 2004; Pertwee, 2008) , inhibiting cAMP with significantly lesser efficacies than CP55,940 (P < 0.05). Following PTX pretreatment, however, inhibition of cAMP synthesis was no longer evident. Instead, the majority of agonists stimulated cAMP synthesis above that produced by forskolin alone. Agonist potencies were significantly reduced in comparison with their potencies at inhibiting cAMP production (interaction effects, P < 0.05; (Table 2 ) was performed to compare agonists' signalling in the Gα i pathway ( Figure 1A ) with signalling in the Gα s pathway ( Figure 1B ), but bias was not detected for any ligand (Table 2) . To determine whether the signalling switch was specific for the CB 1 receptor, concentration-responses with traditional full agonists were performed for hCB 2 receptors ( Figure 1C ) and hD 2 receptors ( Figure 1D ) following pretreatment in the absence and presence of PTX. No evidence was seen for non-Gα i signalling, as PTX pretreatment resulted in a loss of all receptor-mediated cAMP signalling.
High CB 1 receptor expression is sufficient to induce nett Gα s signalling
To determine whether receptor number was sufficient to result in a switch in cAMP signalling from mostly Gα imediated (inhibitory) to mostly Gα s -mediated (stimulatory), cAMP concentration-response stimulations were performed on the HEK cell line stably expressing pplss-3HA-hCB 1 (see below for quantification of receptor expression differences). In these cells (Figure 2A) , the effect of CB 1 receptor activation on cAMP signalling was stimulatory, with most agonists demonstrating greater Gα s pathway efficacies than those seen following PTX-treatment of the non-pplss CB 1 -expressing HEK cells described above (all P < 0.05). THC and BAY again produced negligible stimulation of cAMP ( Figure 2A , Table 1 ). PTX pretreatment of the pplss-3HA-hCB 1 HEK cells did not increase maximum efficacy in the Gα s pathway for WIN55,212-2 or 2AG (P > 0.05; Figure 2B , Table 1 ), despite potencies appearing to increase for all agonists for which curves could be fitted in both pathways (possibly indicating some degree of signalling pathway competition at sub-maximal signalling activities). However, PTX pretreatment did result in increased efficacy for some agonists: most notably THC and BAY (which shifted from no nett change in cAMP, to low-efficacy stimulation of cAMP following PTX treatment), and also (to a lesser extent) AEA and CP55,940 (all P < 0.05; Figure 2A , B; Table 1 ). Representative data are presented, demonstrating mean ± SEM of technical duplicates. Curves were generated by AUC analysis of kinetic CAMYEL biosensor data, which were normalized to basal (0%) and forskolin (100%). 
Figure 2
Concentration-response curves for cAMP formation showing pplss-3HA-hCB 1 HEK signalling, on stimulation with 2.5 μM FSK ('F'; FSK) and a panel of six agonists, following >16 h pretreatment in the absence (A) or presence (B) of PTX. Representative data are presented, demonstrating mean ± SEM of technical duplicates. Curves were created by AUC analysis of kinetic CAMYEL biosensor data, which were normalized to basal (0%) and FSK (100%). Figure 1C) to determine whether the lack of stimulatory signalling following PTX treatment could be explained by a substantially lower receptor number. However, membranes from this cell line were found to contain substantially greater CB 2 receptor protein than the 3HA-hCB 1 HEK cells, at 2541.08 fmol·mg À1 (SEM ± 91.77, n = 6; pK d 9.33, SEM ± 0.12).
The pplss motif is not an inherent determinant of the switch to Gα s signalling
To further investigate the dependence of cAMP signalling on CB 1 receptor expression level and confirm that the observed stimulatory cAMP signalling was not the result of the N-terminal pplss tag, HEK Flp-In ™ cells stably expressing V8-CAMYEL biosensor were transiently transfected with the pplss-3HA-hCB 1 construct to generate a population of cells over which receptor expression ranged widely. Cells were then sorted by FACS into six subpopulations on the basis of surface CB 1 receptor expression level determined by antibody binding to N-terminal HA tags (647 staining intensity, Figure 3A) . The sorted cells were stimulated (CP55,940 concentrationresponse in the presence of 5 μM forskolin) and cAMP levels assayed. In cells with 'very low' to 'moderate' expression, a progressive increase in the magnitude of Gα i -associated cAMP signalling was observed as receptor staining increased ( Figure 3B ). Further increases in receptor expression led to alterations in the overall signalling profile; less efficacious Gα i signalling at 'intermediate' receptor expression, a U-shaped signalling response at 'high' receptor expression (where lower CP55,940 concentrations exerted nett Gα i cAMP effects and higher concentrations exerted nett Gα s cAMP effects) and finally a nett switch in cAMP phenotype to Gα s signalling at 'very high' receptor expression ( Figure 3B ).
Characterization of AM6544: an irreversible antagonist of CB 1 receptors
Pharmacological knockdown involves irreversible binding of an antagonist to the orthosteric binding site, effectively eliminating receptors from the pool available to orthosterically bind ligand. As there are currently no welldescribed irreversible CB 1 antagonists available commercially, the binding of a novel CB 1 irreversible antagonist, AM6544 (Figure 4A ), was characterized under both homogenate and whole cell binding conditions, using [ 3 H]-SR141716A as the probe so that conditions could be kept as constant as possible between homogenate and whole cell assays. Homogenate binding assays were performed on membranes from the same cell line used for whole cell binding assays, pplss-3HA-hCB 1 HEK, and also in membranes from hCB 1 receptor-expressing HEK293F cells ( Figure 4B, C) . These hCB 1 receptor-expressing HEK293F cells were not used in any functional studies reported in this study.
In homogenate binding assays, the pK d of [ 3 H]-SR141716A was determined empirically by homologous competition and was found to be 9.00 (SEM ± 0.24, n = 5). This value was then used for fitting one-site, heterologous binding curves for AM6544 displacement. The resulting pK i for AM6544 was 8.93 (SEM ± 0.08, n = 5 Under whole cell binding conditions, however, the pK d of [
3 H]-SR141716A was right-shifted, to 7.27 (SEM ± 0.06, n = 5), and similarly, the affinity of AM6544 was also reduced: pK i 6.25 (SEM ± 0.06, n = 5). AM6544 irreversible binding was also estimated using the whole cell binding method and was interpreted as being the concentration of ligand that was able to prevent [ 3 H]-SR141716A binding when applied as a 1 h pretreatment and subjected to washing prior to the [ 3 H]-SR141716A incubation. Under these conditions, the pEC 50 of AM6544 knockdown was estimated to be 5.45 (SEM ± 0.11, n = 5). Functional characterization of AM6544 under pretreatment conditions (as used in receptor knockdown studies, see below) in a cAMP signalling assay revealed inverse agonist behaviour, comparable with the effects of SR141716A. As shown in Supporting Information Figure S1 , assay potency under these washout conditions was consistent with the aforementioned high pEC 50 for receptor knockdown.
Systematic pharmacological receptor knockdown reverses pplss-3HA-hCB 1 Gα s signalling
As further evidence to demonstrate the receptor numberdependence of the CB 1 receptor cAMP signalling phenotype, the irreversible CB 1 antagonist, AM6544, was used to systematically reduce receptor number in both the 3HA-hCB 1 and pplss-3HA-hCB 1 HEK stable cell lines. Following pharmacological knockdown, standard concentration-response curves were performed for CP55,940, WIN55,212-2 and THC in the presence of 2.5 μM forskolin. The cAMP signalling of 3HA-hCB 1 HEKs showed decreases in agonist potency and efficacy following pretreatment with μM concentrations of AM6544 ( Figure 5A, C Figure 5B ; 1 μM WIN55,212-2, Figure 5D ) but higher concentrations in the same agonist-response curve resulted in cAMP increases. In cells stimulated with THC ( Figure 5F ), an agonist which does not cause Gα s -like signalling at any concentration in the absence of PTX, inhibitory signalling was also restored following pretreatment with high-concentrations of AM6544. Notably, pretreatment with concentrations of AM6544 that were sufficient to restore Gα i signalling resulted in lower potency agonist responses than the curves arising from signalling in the absence of antagonist, perhaps indicating some degree of competitive binding despite attempted washout of nonirreversibly bound AM6544.
Supplementation of Gα i protein restores inhibitory CB 1 receptor signalling
If the switch to Gα s signalling at high receptor levels is due to Gα i exhaustion, then it would follow that expression levels of either the receptor or the Gα i protein may drive the change in Figure 5 Concentration-response curves for cAMP formation showing 3HA-hCB 1 HEK cells (A, C, E) and pplss-3HA-hCB 1 HEK cells (B, D, F) signalling on stimulation with 2.5 μM forskolin (FSK; 'F') and CP (A, B), WIN (C, D) or THC (E, F), following pretreatment in the presence of increasing concentrations of the irreversible CB 1 receptor antagonist AM6544. Representative data are presented, demonstrating mean ± SEM of technical duplicates. Curves were created by AUC analysis of kinetic CAMYEL biosensor data, which were normalized to basal (0%) and forskolin (100%).
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CB 1 receptor signalling. CB 1 receptors are known to interact with and signal through all three Gα i subtypes (Mukhopadhyay and Howlett, 2005) ; therefore, Gα i 1 expression was supplemented by transfecting untagged GNAI1 (or matched empty vector) into the 3HA-hCB 1 and pplss-3HA-hCB 1 HEK cell lines. cAMP assays revealed no obvious changes to agonist concentration-responses in the 3HA-hCB 1 HEK cell line (whose nett cAMP signal is inhibitory under normal conditions, Figure 6A , C, E). However, in the pplss-3HA-hCB 1 cells, increased Gα i 1 expression resulted in substantially reduced CP55,940 and WIN55,212-2-dependent Gα s signalling efficacy, with inhibitory efficacy evident at some agonist concentrations ( Figure 6B, D) , and restoration of nett inhibitory signalling on stimulation with THC.
Constitutive cAMP signalling in stable 3HA-hCB 1 and pplss-3HA-hCB 1 HEK cells is Gα i -linked
The divergence of agonist-induced signalling for CB 1 receptors at different levels of expression led us to investigate the nature of CB 1 receptor constitutive signalling in each cell line. As expected, in 3HA-hCB 1 cells SR141716A concentration-dependently inhibited constitutive Gα imediated inhibition of cAMP, resulting in an increase in cAMP. Following PTX pretreatment, this effect was lost ( Figure 7A ), indicating that the effect SR141716A inhibited was indeed Gα i -linked. Interestingly, SR141716A treatment of pplss-3HA-hCB 1 HEK cells resulted in a much more pronounced inhibition of Gα i activity, as demonstrated by
Figure 6
Concentration-response curves for cAMP formation showing 3HA-hCB 1 HEK cells (A, C, E) and pplss-3HA-hCB 1 HEK cells (B, D, F) signalling on stimulation with 2.5 μM forskolin (FSK; 'F') and CP (A, B), WIN (C, D) or THC (E, F), following transfection either with supplementary GNAI1 (encoding Gα i 1) or empty vector. Representative data are presented, demonstrating mean ± SEM of technical duplicates. Curves were created by AUC analysis of kinetic CAMYEL biosensor data, which were normalized to basal (0%) and forskolin (100%).
the much larger increase in cAMP. This effect was wholly PTX-sensitive ( Figure 7B ).
pERK, a pathway mediated through multiple G protein subtypes, provides further evidence of Gα i -independent signalling
Time course experiments were performed for activation (phosphorylation) of ERK in both cell lines. In the lowerexpressing 3HA-hCB 1 cells, high concentrations of the agonists CP55,940 and WIN55,212-2 elicited similar pERK maxima of approximately 40% of a 5 min 100 nM PMA stimulation ( Figure 8A, C) , while 10 μM THC elicited a partially efficacious response of approximately 20% of the PMA response ( Figure 8E ). In each instance, this effect was essentially wholly PTX-sensitive, indicating that the pERK responses observed were Gα i -mediated. Interestingly, in the pplss-3HA-hCB 1 cells, the same stimulation conditions elicited larger efficacy responses that were predominantly not PTX-sensitive. Specifically, stimulation with either CP55,940 or WIN55,212-2 ( Figure 8B , D) resulted in pERK signals of approximately 60% of the PMA response in the absence of PTX, and this effect was attenuated by just 10-20% when Gα i was inhibited with PTX. Under these conditions, THC stimulation ( Figure 8F ) demonstrated low efficacy in the 3HA-hCB 1 cells, and a relatively greater proportion of the pERK signal (approximately half) was sensitive to PTX. Time course differences are also apparent in these data: 3HA-hCB 1 HEK cells showed pERK maxima at approximately 3-4 min stimulation times, and this signal decayed rapidly to basal within 10 min, while the pplss-3HA-hCB 1 cells showed an earlier increase in signal (pERK levels at 1 min stimulation already tended to be above basal), a peak at 3-4 min stimulation, but then a delayed decay, as pERK levels tended to plateau at approximately 6-7 min stimulation and gradually returning toward basal pERK state over a period longer than the 30 min of the assay.
Discussion and conclusions
In this study, CB 1 receptor expression level is shown to be a novel determinant of signalling outcome, and this effect was found to be dependent on the cannabinoid agonist used and the expression level of Gα i protein. Assays for cAMP signalling revealed that some 'full' agonists of the CB 1 receptor, particularly CP55,940, elicit maximal signalling in just one of the two pathways characterized, an observation consistent with the findings of Bonhaus et al. (1998) . Additionally, the two CB 1 partial agonists included in the cAMP screen in this study, THC and BAY, showed limited ability to stimulate cAMP, requiring both PTX pretreatment and high CB 1 receptor expression levels for partial Gα s -like efficacy to be unmasked. The receptor number-driven switch from Gα i to Gα s signalling was shown to be specific to CB 1 receptors and could be reversed both by systematic pharmacological knockdown with the novel irreversible antagonist AM6544 (Patent US8084451, 2011) and by increasing the expression level of Gα i 1 protein. Finally, characterization of pERK activation was undertaken to reveal the relative contributions of Gα i activation and alternative pathways to a downstream pathway. These data showed that most (but not all) of the signalling in the lower expressing 3HA-hCB 1 HEK cells is Gα i -mediated and that most of the signalling in the higher expressing pplss-3HA-hCB 1 HEK cells is not Gα i -mediated. To date, the signalling phenotype of the CB 1 receptor has been viewed as almost entirely Gα i -mediated under normal circumstances. At best, this is an oversimplification that has arisen because the easiest, and by far most common, means for assaying Gα i and Gα s protein activity is changes in forskolin-stimulated cAMP. An obvious but inherent limitation of this endpoint, however, is that it is not equipped to distinguish contributions of the different G protein subtypes to the total signal, a problem that originates from the mutually antagonistic effects that Gα i and Gα s activity exert on the cAMP pathway. Indeed, recent work by Eldeeb
Figure 7
Concentration-response curves showing inhibition by the inverse agonist SR141716A of cAMP signals derived from CB 1 receptor constitutive activity, in both 3HA-hCB 1 (A) and pplss-3HA-hCB 1 (B) HEK cells. SR141716A concentration-response curves were performed each in the presence and absence of forskolin ('F') and PTX. Representative data are presented, demonstrating mean ± SEM of technical duplicates. Curves were created by AUC analysis of kinetic CAMYEL biosensor data, which were normalized to basal (0%) and forskolin (100%). et al. (2016) would suggest that nett cAMP signalling does not necessarily reflect CB 1 receptor-mediated G protein activity, as Gα s protein cycling was elicited concentrationdependently following agonist stimulation under conditions where the nett cAMP effect was inhibitory. The use of PTX to irreversibly and specifically inactivate Gα i proteins is a widely used approach that aids in cAMP phenotype characterization. However, this approach is of limited utility in the context of CB 1 receptor characterization because both the circumstances under which Gα s activity occurs, and the extent to which it exists within canonical signalling, remain uncharacterized. Without a reliable means to eliminate Gα s activity, it is also imponderable as to whether PTX unmasks 'secondary' signalling pathways with magnitude equal to that in the absence of PTX, or whether it effectively drives greater efficacy in the non-preferred pathway simply because of reduced competition of non-preferred effectors for active receptors. (Ross et al., 1998) . The concept of functional selectivity adds further complexity to the characterization of CB 1 receptor signalling (see Urban et al., 2007 for a review) . Qualitative means of estimating bias are frequently confounded by variables such as cell background (e.g. different Gα i and Gα s expression levels) or, in cAMP signalling, concentrations of forskolin (higher concentrations will overstate Gα i activity but understate Gα s activity, and vice versa). An empirical method of analysis that purports to objectively describe functional selectivity (not be influenced by the aforementioned variables) is the Operational model. This approach produces parameters for affinity, K A , and efficacy, τ, based on the classical principle that the two levels of interaction that they represent (agonist-receptor interactions and receptorsignalling proteins interactions, respectively) are contingent for profiling a given signalling response (Black and Leff, 1983) . A value obtained from these variables, termed the transduction coefficient, Δlog(τ/K A ), may therefore be considered an agglomeration of both interactions to allow approximation of an agonist's intrinsic efficacy ('stimulus per receptor') (Kenakin et al., 2012) . Comparisons of the transduction coefficients of different pathways (for example, Gα i and Gα s signalling) are subsequently represented as single values in the form of a bias factor, ΔΔlog(τ/K A ). Operational analysis was performed on the cAMP data included in this study, for 3HA-hCB 1 HEK cells in the absence and presence of PTX (Table 2 ). These data did not reveal significant bias for any agonist. However, it must be noted that neither THC nor BAY elicited any cAMP effects when cells had been pretreated with PTX, and therefore, concentration-response curves could not be fitted, nor operational parameters obtained. A simple EC 50 comparative analysis suggests that if THC and BAY underwent the same potency shift as the other ligands (approximately 100-fold), then responses would still be detectable within this assay. It would follow that the apparent inability of these ligands to signal in the Gα s -like pathway must indicate either a much larger shift in potency or an actual lack of Gα s signalling efficacy. Either way, these explanations indicate that THC and BAY are both biased toward the inhibitory pathway and against the stimulatory pathway.
BJP
In this study, experiments of two different designs were performed to demonstrate the role of receptor number in the reported signalling switch for CB 1 receptors. The first, sorting of HEK cells transiently transfected with a construct for pplss-3HA-hCB 1 by FACS (Figure 3) , revealed in 'very low' to 'medium'-expressing cells a progressive increase in inhibitory cAMP signalling, then (with continued increases in receptor expression) a gradual loss of efficacy in the inhibitory pathway, and ultimately nett stimulatory cAMP signalling. The reduction in Gα i signalling at 'intermediate' receptor expression probably indicates the stimulatory signalling component acting competitively with Gα i for receptors -as more receptors are activated, Gα i protein saturation may be occurring as Gα s recruitment increases. Significantly, this suggests that the switch in CB 1 receptor signalling from Gα i to Gα s is dependent on the expression of all three proteins, and potentially other accessory proteins. We hypothesize that the CB 1 receptor possesses high affinity for Gα i , but that this is a relatively low-efficacy signalling pathway. Conversely, the CB 1 receptor has lower affinity for Gα s , but this pathway has higher intrinsic activity and is therefore capable of overwhelming the effects of Gα i . Certainly, the availability and abundance of G protein effectors has already been shown to contribute to alterations in signalling for other GPCRs (Nasman et al., 2001) . It is also possible that cAMP increases results from increased activation of Gα i -insensitive adenylate cyclase (AC) isoforms. HEK cells express the transcripts of multiple isoforms of AC (Atwood et al., 2011) . Different AC isoforms are modulated by different Gα subtypes: all nine AC isoforms are sensitive to stimulation by Gα s/Olf family proteins, but some isoforms (e.g. AC2, 3, 4 and 7) are not directly regulated by Gα i (Dessauer, 2009) .
The second assay type that demonstrated the CB 1 receptor specificity of the switch involved systematic pharmacological knockdown with the novel antagonist AM6544. In order to determine compound affinity, homogenate binding competition-displacement assays were performed and revealed low nanomolar-range affinity. However, in live cell functional assays, micromolar concentrations of AM6544 were required in order for receptor knockdown to be observed ( Figure 5 ) -a difference in concentration that is incongruent with simple occupancy. Further affinity characterization involved whole cell binding assays, which were performed under matched conditions to functional assays ( Figure 5 ). As reported, this assay type revealed a right-shifted micromolar-range pK i and a similar right-shift in SR141716A affinity, emphasizing the dependence of ligand binding on assay conditions. AM6544 was found to concentrationdependently cause a switch of nett stimulatory cAMP signalling back to canonical inhibitory signalling in the pplss-3HA-hCB 1 cells ( Figure 5B , D, F), although pretreatment with even very high concentrations (100 μM) failed to completely abolish signalling, probably indicating both that only a portion of receptors were AM6544-occupied and therefore irreversibly blocked under these assay conditions, and that the cAMP pathway has a substantial degree of receptor reserve.
Experiments to increase Gα i expression by transfection were performed to investigate the influence of G protein expression level on the signalling switch ( Figure 6 ). No substantial differences were observed in the signalling of the 3HA-hCB 1 cells, which signal through Gα i under usual circumstances ( Figure 6A , C, E). In the pplss-3HA-hCB 1 cells, supplementary Gα i 1 expression dramatically altered the concentration-response curves, producing U-shaped concentration-response curves for CP55,940 and WIN55,212-2 and resulting in an inhibitory curve for THC ( Figure 6B, D, F) . The incomplete reversal of signalling with CP55,940 and WIN55,212-2 probably arises due to our assay design, wherein partial transfection efficiency resulted in only a proportion of cells receiving the GNAI1 construct by transfection, and therefore, a range of Gα i 1 expression levels were assayed, including a proportion of cells with no additional Gα i 1 expression. Interestingly, however, in these assays, agonist efficacies align with Gα pathway bias:
CP55,940 exhibits partial efficacy in the Gα s -like pathway in the absence of PTX and demonstrates almost no nett signalling at 1 μM CP55,940 following GNAI1 transfection ( Figure 6B) ; WIN55,212-2 exhibits full efficacy in the Gα s -like pathway and demonstrates less pronounced Gα i rescue in cells overexpressing Gα i ( Figure 6D) ; and THC exhibits no efficacy in the Gα s -like pathway in the absence of PTX, while also being most amenable to demonstrating nett Gα i rescue following GNAI1 transfection, being the only agonist for which an inhibitory concentration-response curve could be fitted ( Figure 6F) . Similarly, it is worth noting that at the ratios at which CB 1 receptors and its signalling effectors are expressed following GNAI1 transfection in this assay, functional bias is genuinely druggable: for example, 10 μM WIN55,212-2 ( Figure 6D ) results in a nett stimulatory cAMP signalling response, while 1 μM THC ( Figure 6F ) results in a nett inhibitory signal.
Characterization of the differential constitutive signalling of the 3HA-hCB 1 and pplss-3HA-hCB 1 HEK cells was based on the Gα i exhaustion hypothesis that under unstimulated conditions, irrespective of receptor expression level, receptors are less likely to be limited for their preferred G protein effector because a minority of receptors are in an active conformation at any moment. The inverse agonist SR141716A induced concentration-dependent stimulation of cAMP in both cell lines (Figure 7 ), and these effects were PTX-sensitive, indicating that these were completely mediated by Gα i . Intriguingly, this results in a situation in pplss-3HA-hCB 1 cells where stimulation with both agonists and inverse agonists has the same effect on signalling, to increase cAMP, albeit by different mechanisms.
Although cAMP assays facilitated substantial characterization of the interplay between receptor number and signalling outcome, the mutually antagonistic consequences of Gα i and Gα s activation on cAMP levels limit ability to discern activation states for each distinct pathway. Characterization of pERK activation in 3HA-hCB 1 and pplss-3HA-hCB 1 HEK cells was undertaken in order to better observe an effect of concurrent activity in the Gα i pathway and alternative Gα s -like pathway and also to examine a downstream consequence of the CB 1 receptor signalling switch. In a result which further extends understanding of the mechanism of the signalling switch, the pERK signal in 3HA-hCB 1 cells was PTX sensitive in every condition ( Figure 8A , C, E), but in pplss-3HA-hCB 1 cells, it was predominantly PTX-independent, suggesting that the alternative signalling pathway may not simply exist additively with Gα i signalling (as required by the Gα i exhaustion hypothesis) but may replace it, in agreement with a pleiotropic switch mechanism (Maudsley et al., 2005) . Significantly, however, it is possible that the pathway mediating the non-PTX-sensitive pERK signal in the pplss-3HA-hCB 1 cells is not the same as the Gα s -like signal that gives rise to stimulatory cAMP signalling: CB 1 receptor coupling to Gα q has also been reported previously (Lauckner et al., 2005) , and this pathway has also been shown to elicit ERK phosphorylation responses (Asimaki and Mangoura, 2011) .
Taken together, the data we present support more than one mechanism for the switch from the canonical Gα i pathway to the alternative Gα s -like pathway: the central idea of receptor number driving the switch and the fact that it can be reversed competitively by altering G protein expression strongly support receptor coupling promiscuity and affinity/efficacy interactions that underpin the Gα i hypothesis; however, the apparent change in signalling balance between Gα i and other effectors in pERK characterization (as opposed to the alternative effectors simply adding to the total signal) better supports a pleiotropic switch mechanism. The potential for more than one signalling switch mechanism is significant from a biomedical perspective. This is because only the pleiotropic mechanism is directly targetable pharmacologically by design of a biased agonist (it requires that stabilization of a particular receptor conformation is sufficient to drive differential signalling), whereas the Gα i exhaustion mechanism requires both receptor agonism and a secondary means to either promote coupling of the favoured G protein or diminish the activity of the disfavoured one. In development of CB 1 receptor-targeted interventions, the ability to target one Gα pathway over another will be of interest therapeutically. For example, in an in vitro model of Huntington's disease, CB 1 receptor Gα s -mediated increases in cAMP have been found to exacerbate cell death by promoting aggregation of mutant huntingtin (Scotter et al., 2010) . Similarly, in a different in vitro Huntington's disease model, CB 1 receptor-mediated Gα i activity has recently been suggested to be therapeutically beneficial, as Gα i -mediated pERK is substantially reduced in diseased cells compared with matched controls, and agonists that demonstrated Gα i bias in those assays were shown to improve cell viability .
One of the greatest remaining obstacles in biomedical sciences generally is the difficulty in relating easily characterized near-signalling phenotypes with whole celllevel endpoints, as mid-stream signalling pathways are relatively poorly characterized and diverge greatly between different cell types and disease states -indeed, a recent review by Velasco et al. (2016) observed that oncogenically transformed cells may exhibit different signalling phenotypes to non-transformed cells and that the molecular reasons for this are unknown. An early study into the effects of cannabinoids on cancer growth revealed that THC treatment inhibited growth of C6 rat glioma cells and induced cell death (Sanchez et al., 1998) , a finding now supported by other studies (Gomez del Pulgar et al., 2002; Salazar et al., 2009) . Confusingly, however, more recent data suggests that blockade of CB 1 receptors can also lead to apoptosis in glioma cells and primary human cells (Ciaglia et al., 2015) , meaning that agonism and antagonism of CB 1 receptors may not confer opposite effects on cell fate, even in related cell types. Additionally, high expression of CB 1 receptors has been shown to correlate with poor prognosis in prostate cancer (Chung et al., 2009; Fowler et al., 2010) as well as stage two microsatellite stable colorectal cancer (Gustafsson et al., 2011) . These endpoints have not been associated with near-signalling phenotypes, but one study to date has revealed that astrocytoma subclones signal through the pro-survival Akt pathway in a manner dependent on high expression of CB 1 receptors (Cudaback et al., 2010) , a finding that was replicated in prostate cancer tissue (Cipriano et al., 2013) . Relatedly, an up-regulation of CB 1 receptors has been reported in a variety of other cancers, including Hodgkin lymphoma (Benz et al., 2013) , human epithelial ovarian tumours (Messalli et al., 2014) and stage four colorectal cancer (Jung et al., 2013) and has been shown to correlate with disease severity in the latter two cases. Thus, substantial conflicts remain in the literature and emphasize the complex interconnections between CB 1 receptor near signalling phenotypes and downstream endpoints such as cell fate. Our study may help to provide a basis for deconvoluting the conflicting data regarding CB 1 receptor near-signalling and cell fate, though much more research is required in order to understand the roles that the signalling switch plays in normal physiology and disease and the ways in which downstream endpoints are affected.
